Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Bisphosphonate-induced osteonecrosis of the jaw: medical implications and dental complications

Gowri, Sivaramakrishnana; Kannan, Sridharanb

doi: 10.1097/FAD.0000000000000007
Original Article

Summary Bisphosphonates are widely used to treat osteoporosis. They inhibit normal bone turnover by inducing osteoclast apoptosis. This impedes normal remodelling, thereby preventing further deterioration in bone architecture. However, use of bisphosphonates for some years can lead to accumulation of old fragile bone, occlusion of haversian sinuses, and ultimately osteonecrosis and sequestrum formation. Dental extraction and other invasive dental procedures have been identified as risk factors for the development of bisphosphonate-induced osteonecrosis of the jaw. The role of a dentist is, in combination with a physician, to prevent and treat bisphosphonate-induced osteonecrosis of the jaw.

aDepartment of Prosthodontics

bDepartment of Pharmacology, Subharti Medical College, Meerut, India

Correspondence to Dr Kannan Sridharan, MD, DM, FICS, Assistant Professor, Department of Pharmacology, Subharti Medical College, Delhi-Haridwar Bypass Road, Meerut 250005, Uttar Pradesh, India. Tel: +91 8192902803; e-mail:

Editor: R E Ferner, MSc, MD, FRCP, Director of the West Midlands Centre for Adverse Drug Reaction Reporting and Consultant Physician at City Hospital, Birmingham, UK. Assistant Editor: Mr C Anton, MA, MEng. Editorial Board: Australia: Dr M Kennedy, Professor G M Shenfield, Denmark: Professor J S Schou; England: Dr J K Aronson; India: Professor N Gogtay; Netherlands: Professor C J van Boxtel, Dr B H Ch Stricker; New Zealand: Dr T Maling; Scotland: Dr D N Bateman; Wales: Professor P A Routledge.

Copyright © 2014 Wolters Kluwer Health, Inc. All rights reserved.